PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Hemostasis and Thrombosis Unit, Division of Hematology, Cliniques universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.\', \'Pediatric Hematology, Emma Children\'s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.\', \'Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK.\', \'Fondazione IRCCS Ca\' Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.\', \'Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.\', \'European Association for Haemophilia and Allied Disorders (EAHAD), Brussels, Belgium.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1111/hae.14372
?:hasPublicationType
?:journal
  • Haemophilia : the official journal of the World Federation of Hemophilia
is ?:pmid of
?:pmid
?:pmid
  • 34191397
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34191397>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34191397>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all